Ionis Pharmaceuticals (IONS) Expected to Release Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS) is projected to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($1.22) per share and revenue of $181.56 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 9:00 AM ET.

Ionis Pharmaceuticals Stock Performance

NASDAQ:IONS opened at $41.24 on Tuesday. Ionis Pharmaceuticals has a 1 year low of $41.19 and a 1 year high of $86.74. The firm has a 50 day moving average of $48.65 and a 200-day moving average of $66.63. The company has a current ratio of 7.89, a quick ratio of 7.73 and a debt-to-equity ratio of 3.07. The stock has a market capitalization of $6.85 billion, a P/E ratio of -11.92 and a beta of 0.38.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on IONS. HC Wainwright reiterated a “buy” rating on shares of Ionis Pharmaceuticals in a research report on Thursday, October 22nd. Royal Bank Of Canada decreased their target price on Ionis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Oppenheimer restated an “outperform” rating and issued a $85.00 target price on shares of Ionis Pharmaceuticals in a research note on Thursday, September 24th. Barclays lowered their target price on Ionis Pharmaceuticals from $90.00 to $85.00 and set an “overweight” rating for the company in a research note on Wednesday, September 9th. Finally, UBS Group assumed coverage on shares of Ionis Pharmaceuticals in a research report on Thursday, October 15th. They set a “buy” rating and a $88.00 price target on the stock. Nineteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $89.48.

Insiders Place Their Bets

In other Ionis Pharmaceuticals news, EVP Shannon Devers sold 1,357 shares of the company’s stock in a transaction on Friday, October 16th. The stock was sold at an average price of $43.54, for a total transaction of $59,083.78. Following the transaction, the executive vice president owned 17,811 shares of the company’s stock, valued at approximately $775,490.94. This represents a 7.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 1.81% of the stock is owned by company insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing medicines using antisense technology. Its platform is designed to selectively target RNA and regulate the production of disease-related proteins. The company develops therapies for neurological, cardiovascular and metabolic, and rare diseases.

Ionis has developed and commercialized medicines both independently and through collaborations with larger pharmaceutical companies. Its marketed or partnered products include Spinraza (nusinersen) for spinal muscular atrophy, Tegsedi (inotersen) and Wainua (eplontersen) for hereditary transthyretin amyloidosis, and Tryngolza (olezarsen) for familial chylomicronemia syndrome.